Logo

Genentech Signs a Clinical Trial Collaboration with Arcus for Colorectal and Pancreatic Cancers

Share this

Genentech Signs a Clinical Trial Collaboration with Arcus for Colorectal and Pancreatic Cancers

Shots:

  • The companies collaborate for the evaluation of novel candidates with Arcus’s AB928 utilizing the MORPHEUS P-Ib/II platform with upfront randomization versus control groups in two studies. The companies will supply its anti-cancer agents and will jointly find the studies
  • The two studies are: The first study will assess AB928 + Tecentriq + regorafenib- Tecentriq + regorafenib vs regorafenib monothx in patients with 3L mCRC; the second study will assess AB928 + atezolizumab + gemcitabine/nab-paclitaxel vs gemcitabine/nab-paclitaxel in patients with 1L mPDAC
  • AB928 is the novel dual adenosine A2aR/A2bR receptor antagonist designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and is being evaluated in P-Ib/II across multiple indications

Click here to read full press release/ article | Ref: PRNewswire | Image: WSJ


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions